Michael Mullette

Amy Emerson, the CEO of Lykos Therapeutics, has stepped down from her role at the company, the WSJ reported. This announcement comes nearly a month after the Food and Drug Administration (FDA) rejected Lykos’s application for its ecstasy-based therapy intended to treat post-traumatic stress...

In the current psychedelics landscape, one of the most important topics is compound legality.  While it's possible that MDMA-assisted therapy will eventually be federally approved in the U.S., what should investors consider when looking at a prospective business? The 2023 edition of...

Michael Mullette, a former Moderna (NASDAQ: MNRA) vice president is taking a senior leadership position in the MAPS Public Benefit Corporation, a biotech company in the psychedelics sector. The MAPS PCB is a for-profit company wholly owned by the Multidisciplinary Association for Psychedelic...